Cancer risks in recipients of renal transplants: a meta-analysis of cohort studies.
Cancer risks in recipients of renal transplants: a meta-analysis of cohort studies. Oncotarget. 2018 Mar 16;9(20):15375-15385 Authors: Wang Y, Lan GB, Peng FH, Xie XB Abstract Renal transplantation is associated with an increased risk of cancers at multiple sites; however, the relationships between increased cancer risk and participant characteristics remain unclear. We searched PubMed, Embase, and the Cochrane Library to identify prospective observational studies performed up to July 2017. Totally 11 prospective studies reported data on 79,988 renal transplant recipients were included. Renal transplant recipients were found to display a higher risk of all cancers (standard incidence ratio [SIR]: 2.89; 95% CI: 2.13-3.91; P
Publication date: Available online 27 March 2020Source: Journal of Vascular and Interventional RadiologyAuthor(s): Jin Woo Choi, Jeong Min Lee, Hyo-Cheol Kim, Myungsu Lee, Saebeom Hur, Hwan Jun Jae, Jin Wook Chung
Publication date: Available online 28 March 2020Source: Academic RadiologyAuthor(s): Stanzione Arnaldo, Renato Cuocolo, Del Grosso Renata, Nardiello Anna, Romeo Valeria, Travaglino Antonio, Raffone Antonio, Bifulco Giuseppe, Zullo Fulvio, Insabato Luigi, Maurea Simone, Pier Paolo Mainenti
Authors: Li W, Zhou Y, Shang C, Sang H, Zhu H Abstract Background: Proton pump inhibitor (PPI) and other acid-suppressing drugs are widely used in the treatment of gastrointestinal ulcer, upper gastrointestinal bleeding, gastritis, and gastric cancer (GC). About 80% of GC patients receive acid suppression treatment. PPI suppresses the production of gastric acid by inhibiting the function of H+/K+-ATPase in gastric parietal cells and raises the pH value to achieve therapeutic purposes. Some studies have found that PPI had a certain antitumor effect in the proliferation and apoptosis of tumor cells. But the effects o...
Publication date: Available online 27 March 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Srinivasa R. Rao, Nasullah K. Alham, Elysia Upton, Stacey McIntyre, Richard J. Bryant, Lucia Cerundolo, Emma Bowes, Stephanie Jones, Molly Browne, Ian Mills, Alastair Lamb, Ian Tomlinson, David Wedge, Lisa Browning, Korsuk Sirinukunwattana, Claire Palles, Freddie C. Hamdy, Jens Rittscher, Clare Verrill
Publication date: Available online 13 March 2020Source: The Journal of Molecular DiagnosticsAuthor(s): Riccardo Giannini, Gemma Zucchelli, Mirella Giordano, Clara Ugolini, Roberto Moretto, Katarzyna Ambryszewska, Michele Leonardi, Elisa Sensi, Federica Morano, Filippo Pietrantonio, Chiara Cremolini, Alfredo Falcone, Gabriella Fontanini
Authors: Quaglino F, Manfrino L, Cestino L, Giusti M, Mazza E, Piovesan A, Palestini N, Lauro C, Castellano E Abstract Parathyroid carcinoma (PC) is a rare disease responsible for about 1% of primary hyperparathyroidism (PHPT) cases. PC usually has an indolent course, tough to differentiate from the benign causes of PHPT, and the only certain diagnosis is histologic. The gold standard surgical treatment is the en bloc resection associated with the homolateral thyroid loboistmectomy. The aim of this study was to underline the main differences between PC and benign PHPT, along with gathering epidemiological knowledge...
CONCLUSION: This case report demonstrates a possible severe adverse effect of the immunomodulatory drug ibrutinib and the importance of a multidisciplinary approach in its diagnosis. Since PML is a rare but highly fatal disease, it is of utmost importance to be aware of the possible connection with the use of this drug to prevent missed or delayed diagnosis, considering that timely therapeutic intervention is crucial for improved prognosis. . PMID: 32213285 [PubMed - as supplied by publisher]
Authors: Setsu T, Tsuchiya A, Terai S PMID: 32213762 [PubMed - as supplied by publisher]
In conclusion, the decreased numbers of VZV-specific CD8+T-cells during the acute phase and VZV-specific CD4+T-cells during the convalescent phase of disease may account for severe varicella in immunocompromised children. PMID: 32213753 [PubMed - in process]
This study aims to analyze survival rates in acute lymphocytic leukemia in the city of São Paulo, Brazil, from 1997 to 2013, according to sex, age bracket, and administrative region. This was a longitudinal study to calculate survival rates. Data on new cases of leukemia in the age bracket 0 to 14 years of age were collected from the database in the Population-Based Cancer Registry of the city of São Paulo. Population and mortality data were obtained from the Brazilian Health Informatics Department. The sample included children 0 to 14 years of age diagnosed with leukemia from 1997 to 2013, living in the city...
More News: Bladder Cancer | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Cancer of the Uterus | Carcinoma | Colon Cancer | Colorectal Cancer | Databases & Libraries | Gastric (Stomach) Cancer | Gastroenterology | Hepatocellular Carcinoma | Kidney Cancer | Lip Cancer | Liver Cancer | Lung Cancer | Lung Transplant | Lymphoma | Melanoma | Non-Hodgkin's Lymphoma | Nonmelanoma Skin Cancer | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Prostate Cancer | Renal Cell Carcinoma | Skin | Skin Cancer | Study | Thyroid | Thyroid Cancer | Transplant Surgery | Transplants